Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mismatch-repair-deficient endometrial cancer, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether chemotherapy can be dropped in favour of immunotherapy alone.
Why a third of deficient tumours do not respond to checkpoint blockade.
Getting germline testing to every woman with an unmethylated deficient tumour.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.
OS 44.
A milestone in how this cancer is treated.